Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Target Price at $11.25

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) have received a consensus rating of "Buy" from the six research firms that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $11.25.

Several research analysts have recently commented on RVPH shares. EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a "strong-buy" rating in a report on Monday, September 23rd. Roth Capital raised Reviva Pharmaceuticals to a "strong-buy" rating in a research report on Friday. Maxim Group raised Reviva Pharmaceuticals from a "hold" rating to a "buy" rating and set a $7.00 price objective for the company in a report on Friday. Finally, Roth Mkm started coverage on Reviva Pharmaceuticals in a report on Friday. They set a "buy" rating and a $7.00 target price on the stock.

Institutional Trading of Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC grew its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) by 17.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 278,496 shares of the company's stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 63.18% of the company's stock.

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH traded up $0.01 during mid-day trading on Friday, reaching $1.88. 4,428,758 shares of the company's stock were exchanged, compared to its average volume of 3,583,320. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $4.83. The business's fifty day simple moving average is $1.56 and its two-hundred day simple moving average is $1.29. The firm has a market capitalization of $62.87 million, a PE ratio of -1.69 and a beta of -0.12.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.